Skip to main content
Figure 4 | Breast Cancer Research

Figure 4

From: Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifen

Figure 4

HMG-CoAR protein expression is associated with tamoxifen response in Cohort II. (a) Kaplan-Meier estimate of recurrence-free survival comparing 2 years of tamoxifen treatment with no adjuvant treatment in 3-hydroxy-3-methylglutharyl-coenzyme A reductase (HMG-CoAR)-negative tumors. (b) Kaplan-Meier estimate of recurrence-free survival comparing 2 years of tamoxifen treatment with no adjuvant treatment in HMG-CoAR-positive tumors. (c) Kaplan-Meier estimate of recurrence-free survival in all estrogen receptor (ER)-positive tumors. (d) Kaplan-Meier estimate of recurrence-free survival in tamoxifen-treated ER-positive tumors. (e) Kaplan-Meier estimate of recurrence-free survival in untreated ER-positive tumors. HR, hazard ratio.

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us